Changing interest among physicians toward pneumococcal vaccination throughout the twentieth century

Journal of the History of Medicine and Allied Sciences
Powel Kazanjian

Abstract

Interest in using pneumococcal vaccination among physicians has come full circle since the early twentieth century. Interest first arose during an epidemic among South African gold miners when a potential therapeutic agent, ethylhydrocupreine, caused significant toxicities. When a safe and effective vaccine became available in 1946, interest in using it paradoxically waned as its introduction coincided with the advent of penicillin. Physicians believed that this effective new antibiotic would change pneumonia from a dreaded infection to a casual, infrequent occurrence. The manufacturer was unable to promote vaccine use and withdrew it from the market. Enthusiasm for vaccination remained low long after limitations in antibiotic therapy of pneumococcal infections became clear in the 1960s and a new vaccine once again became available in 1978. Interest in vaccination was eventually renewed in the 1990s when the propagation of pneumococcal resistance to multiple agents diminished the complete confidence that physicians had in antibiotics and when populations at risk for infection were expanding. Scientific evidence of vaccine efficacy, demonstrated in 1944 and 1977, has not alone been sufficient to convince physicians to use vaccin...Continue Reading

Citations

Apr 5, 2013·The Consultant Pharmacist : the Journal of the American Society of Consultant Pharmacists·Jeannette Y Wick
Jan 19, 2012·Human Vaccines & Immunotherapeutics·Jonathan A McCullers, Victor C Huber
Jan 5, 2020·Journal of Biomedical Science·Ravinder MettuChung-Yi Wu
Nov 11, 2005·Pediatric Emergency Care·Mary Anne Jackson, Angela Myers
Aug 14, 2012·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·J D Grabenstein, K P Klugman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Related Papers

The Pediatric Infectious Disease Journal
T J O'DempseyB Greenwood
Occupational and Environmental Medicine
I Kleinschmidt, G Churchyard
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology
G A Bruyn, R van Furth
© 2021 Meta ULC. All rights reserved